Product Pathways - NF-kB Signaling
NLRX1 Antibody #8583
|8583S||100 µl (10 western blots)||---||In Stock||---|
|8583||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting, IP=Immunoprecipitation
Species predicted to react based on 100% sequence homology: Monkey.
Specificity / Sensitivity
NLRX1 Antibody recognizes endogenous levels of total NLRX1 protein. This antibody cross-reacts with a 65 kDa protein of unknown origin.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys441 of human NLRX1 protein. Antibodies are purified by protein A and peptide affinity chromatography.
The nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family of proteins is a diverse family of cytoplasmic innate immune receptors. They are characterized by the presence of an amino-terminal effector domain, which is often either a caspase activation and recruitment domain (CARD) or a pyrin domain (PYD), followed by a NACHT domain and carboxy-terminal leucine-rich-repeats (LRR) involved in recognition of pathogen-associated molecular patterns (PAMPs) (1). NLR proteins play a variety of roles during the innate immune response including pathogen sensing, transcriptional activation of proinflammatory cytokines through NF-κB, transcriptional activation of type I interferons through IRFs, and formation of inflammasomes leading to activation of inflammatory caspases (1-7).
NLRX1 (CLR11.3/NOD26/NOD5/NOD9) is unique among NLR family members in that it contains an amino-terminal mitochondrial targeting sequence resulting in localization to the mitochondria (8,9). In contrast to most NLR proteins, NLRX1 has been shown to act as a negative regulator of innate immune responses through inhibition of MAVS-Rig-I signaling, as well as inhibition of Toll-like receptor (TLR)-mediated NF-κB activation (9-11). In addition, overexpression of NLRX1 enhanced the production of reactive oxygen species (ROS), resulting in prolonged NF-κB and JNK signaling in response to TNF-α (8).
- Elinav, E. et al. (2011) Immunity 34, 665-79.
- Inohara, N. et al. (1999) J Biol Chem 274, 14560-7.
- Ogura, Y. et al. (2001) J Biol Chem 276, 4812-8.
- Sabbah, A. et al. (2009) Nat Immunol 10, 1073-80.
- Mariathasan, S. et al. (2004) Nature 430, 213-8.
- Agostini, L. et al. (2004) Immunity 20, 319-25.
- Martinon, F. et al. (2002) Mol Cell 10, 417-26.
- Tattoli, I. et al. (2008) EMBO Rep 9, 293-300.
- Moore, C.B. et al. (2008) Nature 451, 573-7.
- Allen, I.C. et al. (2011) Immunity 34, 854-65.
- Xia, X. et al. (2011) Immunity 34, 843-53.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.